Global Car T-Cell Therapy Market Size, Share, Growth, Trends, and Forecast (2024 - 2031)
Global Car T-Cell Therapy Market Scope: Historical Data (2021 – 2022), Base Year (2023), Forecast Period (2024 – 2031)
Market Segmentation: By Type (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and Others), Application (Leukemia, Lymphoma, Multiple Myeloma, Autoimmune Disorders, and Other Applications), End User (Hospitals, Cancer Care Treatment Centers, and Other End Users), and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Market Overview
The Global Car T-Cell Therapy Market was valued at USD 3,406.0 million in 2023 and is expected to reach USD 18,218.4 million by 2031 while growing at a CAGR of 23.3% during the forecast period (2024-2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Market Dynamics
This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global car t-cell therapy market growth. CAR-T therapy is an innovative immunotherapy for specific cancers. It modifies a patient's T cells by adding a chimeric antigen receptor (CAR) to recognize cancer cell proteins. After modification, these T cells are multiplied in the lab and reintroduced into the patient, attacking and eliminating cancer cells with the targeted protein.
The rising cancer cases and backing from regulatory bodies like the FDA and EMA are expected to drive Car T-Cell Therapy market growth. Challenges, such as high treatment costs and safety concerns, could hinder its expansion.
Furthermore, the global car t-cell therapy industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.
Segmentation – By Type Analysis
The Global Car T-Cell Therapy Market is segmented among Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and Others, based on Type. In 2023, Yescarta accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Segmentation – By Application Analysis
The Global Car T-Cell Therapy Market is segmented among Leukemia, Lymphoma, Multiple Myeloma, Autoimmune Disorders, and Other Applications, based on Application. In 2023, Lymphoma accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Global Car T-Cell Therapy Market: Regional Analysis
Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Competitive Landscape
Some of the key players operating in the market are Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson, Eli Lilly and Company, Sorrento Therapeutics, Inc., ACROBiosystems, Celyad Oncology, Sangamo Therapeutics, Inc., and Servier Laboratories.
Table of Contents:
1. Research Methodology and Market Scope
Research Methodology
Market Scope
2. Executive Summary
3. Global Car T-Cell Therapy Market Dynamics
Drivers
Restraints
Opportunity
4. Global Car T-Cell Therapy Industry Analysis
PEST Analysis
Porter's Five Force Analysis
Recent Deals Analysis
5. Global Car T-Cell Therapy Market Segmentation, By Type
Global Car T-Cell Therapy Market Share Analysis, By Type
Global Car T-Cell Therapy Market Growth Analysis, By Type
Global Car T-Cell Therapy Market Trends, By Type
o Abecma
o Breyanzi
o Kymriah
o Tecartus
o Yescarta
o Others
6. Global Car T-Cell Therapy Market Segmentation, By Application
Global Car T-Cell Therapy Market Share Analysis, By Application
Global Car T-Cell Therapy Market Growth Analysis, By Application
Global Car T-Cell Therapy Market Trends, By Application
o Leukemia
o Lymphoma
o Multiple Myeloma
o Autoimmune Disorders
o Other Application
7. Global Car T-Cell Therapy Market Segmentation, By End User
Global Car T-Cell Therapy Market Share Analysis, By End User
Global Car T-Cell Therapy Market Growth Analysis, By End User
Global Car T-Cell Therapy Market Trends, By End User
o Hospitals
o Cancer Care Treatment Centers
o Other End Users
8. Global Car T-Cell Therapy Market Segmentation, By Region
Global Car T-Cell Therapy Market Share Analysis, By Region
Global Car T-Cell Therapy Market Growth Analysis, By Region
Global Car T-Cell Therapy Market Trends, By Region
o North America
o Europe
o Asia Pacific
o Latin America
o Middle East
o Africa
9. Competitive Landscape
Novartis AG *
o Company Overview
o Financial Performance
o Key Development/Strategies
o SWOT Analysis
Bristol-Myers Squibb Company
Gilead Sciences, Inc. (Kite Pharma)
Johnson & Johnson
Eli Lilly and Company
Sorrento Therapeutics, Inc.
ACROBiosystems
Celyad Oncology
Sangamo Therapeutics, Inc.
Servier Laboratories
*Similar analysis will be provided for each company listed above.
